Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and widely used neuromodulation technology. Small sample studies have shown that rTMS treatment can significantly improve the symptoms of Parkinson's disease(PD) and delay the progression of the disease. In order to further explore the effectiveness of rTMS in the treatment of PD and lay the foundation for its clinical promotion, our research team plans to conduct a randomized double-blind controlled study of rTMS in the treatment of PD in multiple centers across the country.
Age ≥ 40 years old;
Meet the diagnostic criteria for idiopathic Parkinson's disease (MDS Diagnostic Criteria for Parkinson's Disease (2015 Edition))[1];
Have no history of drug adjustment within 4 weeks before treatment and the entire study period;
The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4;
Previously head MRI/CT was focal brain injury or severe leukoencephalopathy (Fazekas grade 3 and above);
Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.);
Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment;
There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.
Parallel
transcranial magnetic stimulation
Other interventionThe stimulations were performed by MagStim Rapid2.
Movement Disorder Society- Unified Parkinson's Disease Rating Scale III scores
This is an very common clinical motor estimating scale with 18 items and 140' in total. Higher scores indicate worse symptoms.
Movement Disorder Society- Unified Parkinson's Disease Rating Scale Ⅰ scores
MDS-UPDRS I is used to evaluate the daily life non-motor symptom experience of patients with Parkinson's disease. It includes 13 items with a total score of 52 points. Higher scores indicate worse symptoms.
Movement Disorder Society- Unified Parkinson's Disease Rating Scale Ⅱ scores
MDS-UPDRS II is used to evaluate patients' experience of daily life motor symptoms, such as speech function, eating ability, daily living ability (eating, dressing, hygiene), tremor, walking, etc. It includes 13 items with a total score of 52 points. Higher scores indicate worse symptoms.
Movement Disorder Society- Unified Parkinson's Disease Rating Scale Ⅳ scores
The MDS-UPDRS IV questionnaire assesses the severity of two motor complications in patients: dyskinesias and motor fluctuations, combined with previously known and objective information. It includes 6 items with a total score of 24 points. Higher scores indicate worse symptoms.
Hoehn-Yahr(H-Y) scale
H-Y scale is a standardized instrument used to evaluate the severity of Parkinson's disease. It employs a scoring system that ranges from 1 to 5, with higher scores indicating greater severity of clinical symptoms and a corresponding decline in quality of life. The assessment criteria primarily consider the number of limbs affected, the presence of balance disturbances, and the extent of functional impairment in daily living activities. This scale is valued for its simplicity and practicality, making it a prevalent tool in clinical trials for evaluating Parkinson's disease symptoms.
Click on the lead sponsor to view all of their trials.
